These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 20131403)

  • 1. Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice.
    Spirli C; Okolicsanyi S; Fiorotto R; Fabris L; Cadamuro M; Lecchi S; Tian X; Somlo S; Strazzabosco M
    Hepatology; 2010 May; 51(5):1778-88. PubMed ID: 20131403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice.
    Spirli C; Okolicsanyi S; Fiorotto R; Fabris L; Cadamuro M; Lecchi S; Tian X; Somlo S; Strazzabosco M
    Gastroenterology; 2010 Jan; 138(1):360-371.e7. PubMed ID: 19766642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib.
    Spirli C; Morell CM; Locatelli L; Okolicsanyi S; Ferrero C; Kim AK; Fabris L; Fiorotto R; Strazzabosco M
    Hepatology; 2012 Dec; 56(6):2363-74. PubMed ID: 22653837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease.
    Spirli C; Mariotti V; Villani A; Fabris L; Fiorotto R; Strazzabosco M
    J Hepatol; 2017 Mar; 66(3):571-580. PubMed ID: 27826057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered store operated calcium entry increases cyclic 3',5'-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective cholangiocytes.
    Spirli C; Locatelli L; Fiorotto R; Morell CM; Fabris L; Pozzan T; Strazzabosco M
    Hepatology; 2012 Mar; 55(3):856-68. PubMed ID: 21987453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases.
    Fabris L; Cadamuro M; Fiorotto R; Roskams T; Spirlì C; Melero S; Sonzogni A; Joplin RE; Okolicsanyi L; Strazzabosco M
    Hepatology; 2006 May; 43(5):1001-12. PubMed ID: 16628643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells.
    de Stephanis L; Bonon A; Varani K; Lanza G; Gafà R; Pinton P; Pema M; Somlo S; Boletta A; Aguiari G
    Clin Exp Nephrol; 2017 Apr; 21(2):203-211. PubMed ID: 27278932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The regulatory 1α subunit of protein kinase A modulates renal cystogenesis.
    Ye H; Wang X; Constans MM; Sussman CR; Chebib FT; Irazabal MV; Young WF; Harris PC; Kirschner LS; Torres VE
    Am J Physiol Renal Physiol; 2017 Sep; 313(3):F677-F686. PubMed ID: 28615245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice.
    Amura CR; Brodsky KS; Groff R; Gattone VH; Voelkel NF; Doctor RB
    Am J Physiol Cell Physiol; 2007 Jul; 293(1):C419-28. PubMed ID: 17475663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway.
    Villaume K; Blanc M; Gouysse G; Walter T; Couderc C; Nejjari M; Vercherat C; Cordier-Bussat M; Roche C; Scoazec JY
    Neuroendocrinology; 2010; 91(3):268-78. PubMed ID: 20389030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis.
    Li A; Fan S; Xu Y; Meng J; Shen X; Mao J; Zhang L; Zhang X; Moeckel G; Wu D; Wu G; Liang C
    J Cell Mol Med; 2017 Aug; 21(8):1619-1635. PubMed ID: 28244683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insights on the role of vascular endothelial growth factor in biliary pathophysiology.
    Mariotti V; Fiorotto R; Cadamuro M; Fabris L; Strazzabosco M
    JHEP Rep; 2021 Jun; 3(3):100251. PubMed ID: 34151244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic
    Holditch SJ; Brown CN; Atwood DJ; Lombardi AM; Nguyen KN; Toll HW; Hopp K; Edelstein CL
    Am J Physiol Renal Physiol; 2019 Jul; 317(1):F187-F196. PubMed ID: 31042058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of the proliferation of hypoxia-Induced retinal pigment epithelial cell by rapamycin through the /mTOR/HIF-1α/VEGF/ signaling.
    Liu NN; Zhao N; Cai N
    IUBMB Life; 2015 Jun; 67(6):446-52. PubMed ID: 25988388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ablation of Long Noncoding RNA Hoxb3os Exacerbates Cystogenesis in Mouse Polycystic Kidney Disease.
    Weisser I; Eckberg K; D'Amico S; Buttram D; Aboudehen K
    J Am Soc Nephrol; 2024 Jan; 35(1):41-55. PubMed ID: 37953472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin.
    Mayerhofer M; Valent P; Sperr WR; Griffin JD; Sillaber C
    Blood; 2002 Nov; 100(10):3767-75. PubMed ID: 12393646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease.
    Chen L; Zhou X; Fan LX; Yao Y; Swenson-Fields KI; Gadjeva M; Wallace DP; Peters DJ; Yu A; Grantham JJ; Li X
    J Clin Invest; 2015 Jun; 125(6):2399-412. PubMed ID: 25961459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney disease.
    Kipp KR; Kruger SL; Schimmel MF; Parker N; Shillingford JM; Leamon CP; Weimbs T
    Am J Physiol Renal Physiol; 2018 Aug; 315(2):F395-F405. PubMed ID: 29717938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure to ubiquitinate c-Met leads to hyperactivation of mTOR signaling in a mouse model of autosomal dominant polycystic kidney disease.
    Qin S; Taglienti M; Nauli SM; Contrino L; Takakura A; Zhou J; Kreidberg JA
    J Clin Invest; 2010 Oct; 120(10):3617-28. PubMed ID: 20852388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin.
    Mekahli D; Decuypere JP; Sammels E; Welkenhuyzen K; Schoeber J; Audrezet MP; Corvelyn A; Dechênes G; Ong AC; Wilmer MJ; van den Heuvel L; Bultynck G; Parys JB; Missiaen L; Levtchenko E; De Smedt H
    Pflugers Arch; 2014 Aug; 466(8):1591-604. PubMed ID: 24193408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.